Individual Patient Compassionate Use of Nirogacestat
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT05041036|
Expanded Access Status : Available
First Posted : September 10, 2021
Last Update Posted : September 10, 2021
- Study Details
- Tabular View
- How to Read a Study Record
|Condition or disease||Intervention/treatment|
|Desmoid Tumor NOTCH Gene Mutation Positive Tumors||Drug: Nirogacestat (Gamma Secretase Inhibitor)|
|Study Type :||Expanded Access|
|Expanded Access Type :||Individual Patients|
|See clinical trials of the intervention/treatment in this expanded access record.|
|Official Title:||Individual Patient Compassionate Use of Nirogacestat|
- Drug: Nirogacestat (Gamma Secretase Inhibitor)
Patients will receive nirogacestat tablets to be taken orally.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||Child, Adult, Older Adult|
|Sexes Eligible for Study:||All|
- Patient has a serious, debilitating or life-threatening medical condition with no suitable treatment available, has exhausted current standard of care or declined medically-appropriate treatment for ethical or medical reasons.
- Patient does not qualify to participate in any ongoing clinical trial sponsored by SpringWorks in an accessible geographical location.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05041036
|Contact: Sue Scottfirstname.lastname@example.org|
|Contact: Pamela Papino-Woodemail@example.com|
|Responsible Party:||SpringWorks Therapeutics, Inc.|
|Other Study ID Numbers:||
|First Posted:||September 10, 2021 Key Record Dates|
|Last Update Posted:||September 10, 2021|
|Last Verified:||July 2021|
Neoplasms, Fibrous Tissue
Neoplasms, Connective Tissue
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type